Fusion Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

FUSN Fusion Pharmaceuticals Inc

RDUS Schnitzer Steel Industries Inc

ALEC Alector Inc

LZM Lifezone Metals Ltd

LMRMF Lomiko Metals Inc

SOXL Direxion Daily Semiconductor Bull 3X Shares

OXSQ Oxford Square Capital Corp

BAER Bridger Aerospace Group Holdings Inc

CMRA Comera Life Sciences Holdings Inc

SY So-Young International Inc

Go

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.